Closed Series C funding, raising a total of 2.7 billion yen.

Innovacell K.K. (Headquarters: Shibuya, Tokyo; Representatives: Colin Lee Novick, Jason David Sieger), which aims to improve people’s health and quality of life (QOL) through cell therapy for the treatment of fecal incontinence and urinary incontinence, is pleased to announce that on July 8, we closed our Series C funding with investments from Koei Tecmo Group’s subsidiary, Koei Tecmo Capital, among others. The Series C round raised a total of 2.7 billion yen from both existing and new shareholders.

“As you may know, Koei Tecmo Group is a remarkable corporate group that has continuously created new value over the years, enhancing its performance through investment returns and maintaining a solid financial structure. Their decision to invest in InnovaCell reflects not only their deep resonance with our vision and management but also an appreciation for the novelty of our developing treatment methods and their expectations for InnovaCell’s management. With the closing of Round C, marked by Koei Tecmo Group joining us as a new shareholder, we will focus even more on advancing our business to deliver our treatment to patients suffering from fecal incontinence as quickly as possible, while also meeting the expectations of our shareholders.”